IL10 and visceral leishmaniasis: Importantly, a study with splenic aspirates from visceral leishmaniasis (VL) patients demonstrated that blockade of IL-10 enhanced control of the parasites (40), which provides the experimental foundation for a host-directed therapy where IL-10 would be blocked in VL patients (41).